This homepage documents the journey of a systematic review and individual patient data meta-analysis (IPDMA)
This is an IPDMA of randomized controlled trials that evaluated Janus Kinase (JAK) inhibitors in hospitalized COVID-19 patients. Our main objectives are:
i) To summarize the overall benefit and harm including all available evidence, including data from registered but unpublished eligible trials
ii) To investigate where treatment effects differ between pre-specified subgroups, focusing on severity of disease, COVID-19 vaccination status, comorbidity (incl. immunosuppression), concomitant COVID-19 treatment, and age
iii) To evaluate the safety profile, focusing on cardiac, cardiovascular, and thromboembolic events, and secondary infections
The study protocol is registered on PROSPERO.
This project is funded by EU RESPONSE.
The Team
-
Alain Amstutz
-
Stefan Schandelmaier
-
Benjamin Speich
-
Stephan Schobinger
Patient representative, Bern, Switzerland
-
Dominique Costagliola
-
Alessia Ferrarini
Gastroenterologia ed Endoscopia Digestiva, Ospedali Riuniti Marche Nord, Fano, Italy
-
Giovanni Pomponio
Clinica Medica, Ospedali Riuniti di Ancona, Ancona, Italy
-
Alejandro Morales Ortega
-
David Bernal-Bello
-
Hema Murugesan
Government Stanley Medical College and Hospitals, Chennai, India
-
Monireh Ghazaeian
-
Hannah Ewald
-
Erica Ponzi
-
Johannes Schwenke
-
Christof Schönenberger
-
Clément Massonnaud
-
Thomas Agoritsas
-
José R. Arribas
La Paz University Hospital, Madrid, Spain // PANCOVID trial Team
-
María Teresa García Morales
-
María Jiménez-González
-
Kay Tomashek
-
Seema Nayak
-
Mat Makowski
-
Simon Bond
-
Marius Trøseid
-
Matthias Briel
Send us a message and we will get back to you as soon as possible.